WO1995018602A1 - FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE - Google Patents

FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE Download PDF

Info

Publication number
WO1995018602A1
WO1995018602A1 PCT/US1995/000275 US9500275W WO9518602A1 WO 1995018602 A1 WO1995018602 A1 WO 1995018602A1 US 9500275 W US9500275 W US 9500275W WO 9518602 A1 WO9518602 A1 WO 9518602A1
Authority
WO
WIPO (PCT)
Prior art keywords
pellet
protein
ddavp
microspheres
pellets
Prior art date
Application number
PCT/US1995/000275
Other languages
English (en)
Inventor
Mary Dibiase
Howard Bernstein
Original Assignee
Alkermes Controlled Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Controlled Therapeutics, Inc. filed Critical Alkermes Controlled Therapeutics, Inc.
Priority to AU16770/95A priority Critical patent/AU1677095A/en
Publication of WO1995018602A1 publication Critical patent/WO1995018602A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des systèmes d'administration par voie orale de dDAVP, dans lesquels la dDAVP conserve une bonne activité biologique. Selon le mode de réalisation préféré, on forme des microsphères protéiniques de dDAVP en émulsifiant une solution d'une protéine telle que la zéine et la dDAVP avec un solvant non miscible. Des pastilles contenant les microsphères ainsi produites sont préparées selon un procédé d'extrusion et de sphéroïdisation, et sont placées dans une capsule de gélatine dure. Après administration in vivo de telles capsules à des macaques de Bouffon, la dDAVP biologiquement active est libérée.
PCT/US1995/000275 1994-01-11 1995-01-09 FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE WO1995018602A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16770/95A AU1677095A (en) 1994-01-11 1995-01-09 Oral dosage form of desmopressin (ddavp)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18014294A 1994-01-11 1994-01-11
US08/180,142 1994-01-11

Publications (1)

Publication Number Publication Date
WO1995018602A1 true WO1995018602A1 (fr) 1995-07-13

Family

ID=22659362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000275 WO1995018602A1 (fr) 1994-01-11 1995-01-09 FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE

Country Status (2)

Country Link
AU (1) AU1677095A (fr)
WO (1) WO1995018602A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007139A2 (fr) * 2003-07-15 2005-01-27 Röhm GmbH & Co. KG Forme galenique multiparticulaire contenant des principes actifs peptidiques ou proteiques formules de façon a presenter une action mucoadhesive, et procede de production de cette forme galenique
EP1550439A1 (fr) * 2003-12-29 2005-07-06 Ferring B.V. Procédé pour la préparation d'une forme solide de dosage de Desmopressine
WO2005063202A2 (fr) * 2003-12-29 2005-07-14 Ferring B.V. Procede de preparation d'une forme posologique solide de la desmopressine
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
US7022340B2 (en) 2003-07-25 2006-04-04 Ferring B.V. Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US20120322734A1 (en) * 2002-05-07 2012-12-20 Fein Seymour H Pharmaceutical Compositions Including Low Dosages of Desmopressin
DE102014103271A1 (de) 2014-03-12 2015-09-17 David Plattner Seilsägevorrichtung und Verwendung einer Seilsägevorrichtung
US9539302B2 (en) 2009-06-18 2017-01-10 Allergan, Inc. Safe desmopressin administration
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006286A1 (fr) * 1989-11-06 1991-05-16 Enzytech, Inc. Procede de production de microspheres de proteines
WO1993013753A1 (fr) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Comprimes contenant des medicaments peptidiques, leur fabrication et leur application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006286A1 (fr) * 1989-11-06 1991-05-16 Enzytech, Inc. Procede de production de microspheres de proteines
WO1993013753A1 (fr) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Comprimes contenant des medicaments peptidiques, leur fabrication et leur application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.S. LATHA ET AL: "Glutaraldehyde cross-linked bovine casein microsperes as a matrix for the controlled release of theophylline: in vitro studies.", J. PHARM. PHARMACOL., vol. 46, no. 1, pages 8 - 13 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071057B2 (en) 2001-08-06 2018-09-11 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861582B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US11135171B2 (en) 2001-08-06 2021-10-05 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861583B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10500160B2 (en) 2001-08-06 2019-12-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10076497B2 (en) 2001-08-06 2018-09-18 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064825B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9867784B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064824B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9968559B2 (en) 2001-08-06 2018-05-15 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9877924B2 (en) 2001-08-06 2018-01-30 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9872836B2 (en) 2001-08-06 2018-01-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9867783B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9757341B2 (en) 2001-08-06 2017-09-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20120322734A1 (en) * 2002-05-07 2012-12-20 Fein Seymour H Pharmaceutical Compositions Including Low Dosages of Desmopressin
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US8734849B2 (en) 2003-07-15 2014-05-27 Evonik Roehm Gmbh Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
JP2009513553A (ja) * 2003-07-15 2009-04-02 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング ムコ粘着性組成化ペプチド−又はタンパク質−作用物質を含有する多層粒子形剤形、及びこの剤形の製法
WO2005007139A2 (fr) * 2003-07-15 2005-01-27 Röhm GmbH & Co. KG Forme galenique multiparticulaire contenant des principes actifs peptidiques ou proteiques formules de façon a presenter une action mucoadhesive, et procede de production de cette forme galenique
WO2005007139A3 (fr) * 2003-07-15 2005-05-12 Roehm Gmbh Forme galenique multiparticulaire contenant des principes actifs peptidiques ou proteiques formules de façon a presenter une action mucoadhesive, et procede de production de cette forme galenique
US7022340B2 (en) 2003-07-25 2006-04-04 Ferring B.V. Pharmaceutical composition as solid dosage form and method for manufacturing thereof
WO2005063202A3 (fr) * 2003-12-29 2006-05-18 Ferring Bv Procede de preparation d'une forme posologique solide de la desmopressine
WO2005063202A2 (fr) * 2003-12-29 2005-07-14 Ferring B.V. Procede de preparation d'une forme posologique solide de la desmopressine
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
EP1550439A1 (fr) * 2003-12-29 2005-07-06 Ferring B.V. Procédé pour la préparation d'une forme solide de dosage de Desmopressine
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US9539302B2 (en) 2009-06-18 2017-01-10 Allergan, Inc. Safe desmopressin administration
US11419914B2 (en) 2009-06-18 2022-08-23 Serenity Pharmaceuticals Llc Safe desmopressin administration
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102014103271A1 (de) 2014-03-12 2015-09-17 David Plattner Seilsägevorrichtung und Verwendung einer Seilsägevorrichtung
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Also Published As

Publication number Publication date
AU1677095A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
AU713192B2 (en) Tetrahydrolipstatin containing compositions
CN1154481C (zh) 遮味药物组合物
RU2197227C2 (ru) Фармацевтическая композиция, покрытая энтеросолюбильной оболочкой, и способ ее получения
KR100365572B1 (ko) 서방성조성물및약학조성물의제조방법
AU626031B2 (en) New solid porous unitary form comprising micro-particles and/or nano-particles, and its preparation
JP2960169B2 (ja) 高放出性固体製剤、その製法および用途
US20040166157A1 (en) Palatable controlled-released formulations for companion animals
AU2001294458B2 (en) Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
JPH11515016A (ja) 溶融法によるペプチド含有生分解性ミクロスフェアの製造
WO1998011879A1 (fr) Formes galeniques orales retenues dans l'estomac, pour la liberation controlee de medicaments faiblement solubles et de substance insoluble
WO1995018602A1 (fr) FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE
JPH08509231A (ja) 修飾加水分解植物タンパク質ミクロスフィア及びその製法と用途
JP2000212068A (ja) 薬学的有効物質９０重量％まで含有するペレットの製造方法。
JP2896355B2 (ja) 持続性動物成長ホルモン製剤およびその製造方法
PL202935B1 (pl) Doustny preparat farmaceutyczny o zmiennie nastawianej charakterystyce uwalniania oraz sposób wytwarzania takiego preparatu
JP2003528829A6 (ja) 薬剤学的製剤
JP2004501188A (ja) インスリンの放出制御製剤及びその方法
US7105181B2 (en) Microparticles
UA82268C2 (uk) Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
EP0425298B1 (fr) Préparation à libération retardée d'un chlorhydrate d'un médicament basique
JPH04124127A (ja) マイクロカプセル型徐放性製剤及びその製造法
US20050271708A1 (en) Palatable controlled-release formulation for companion animals
JP5214312B2 (ja) 固形製剤およびその製造方法
JP4459315B2 (ja) 徐放性製剤の製造法
RU2382634C2 (ru) Способ получения пилюль для фармацевтических композиций

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA